RxDoctor Payments Data

Henry Crowley, DO

Anesthesiology · Fall River, MANPI 1215937941

Payments from drug & device makers

$5,429in general payments, 2019–2025

Across 321 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bristol Myers Squibb$535
  • Johnson & Johnson$471
  • Takeda Pharmaceuticals U.S.A., Inc.$411
  • Ardelyx, Inc.$377
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$337
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,405100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,429 in reported general payments places this provider in the 90th percentile of 1,585 anesthesiology providers in Massachusetts.

See all anesthesiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$56,427
Medicare patients
268
Services billed
633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl33$27,772
NucyntaTapentadol Hcl17$13,964
Xtampza ErOxycodone Myristate11$4,149
Pregabalin18$1,876
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$1,456
Oxycodone Hcl103$1,073
Tramadol Hcl68$571
Morphine Sulfate18$415
Morphine Sulfate ErMorphine Sulfate11$411
Fentanyl12$406
Celecoxib14$355
Cyclobenzaprine Hcl27$193
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$160
Eszopiclone12$138
Gabapentin11$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$304$18,11328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,585 anesthesiology providers in Massachusetts.

Other anesthesiology in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →